The most common cause for hospitalization and the hallmark of sickle cell disease (SCD) is
painful vaso-occlusive crisis (VOC). Several studies including our own have documented a …

A randomized double-blind clinical trial was performed to test the safety and efficacy of a low-
molecular-weight heparin, tinzaparin (Innohep®), for the management of acute painful …

We summarize a Cochrane systematic review that was conducted to assess the effects of
low-molecular-weight heparins (LMWH) for managing vasoocclusive crises (VOC) in people …

Background There are no approved treatments for vaso-occlusive crises in sickle cell
disease. Sevuparin is a novel non-anticoagulant low molecular weight heparinoid, with anti …

Sickle-cell disease (SCD) is characterized by frequent and painful vaso-occlusive crises
(VOCs). Various treatments have been evaluated over the years. However, a clear overview …

Sickle-cell disease (SCD) is a wide-spread inherited hemolytic anemia that is due to a point
mutation, leading to the substitution of valine for glutamic acid, causing a spectrum of clinical …

Nearly every component of hemostasis is altered in sickle cell disease (SCD), yet little
evidence exists to guide utilization of venous thromboembolism prophylaxis (VTEP) in this …

Objective Compare time to pain relief (minimum of a 13 mm and 30% reduction) during an
Emergency Department (ED) visit among patients with sickle cell disease (SCD) …

Early diagnosis, treatment, and prevention of a vaso‐occlusive crisis (VOC) are critical to the
management of patients with sickle cell disease. It is essential to differentiate between VOC …

Background While pain is the hallmark of sickle cell disease (SCD), healthcare personnel
are often ill-equipped to adequately treat patients who present in vaso-occlusive crisis …